IGF-1 stands for insulin-like growth factor 1. It is a hormone, mostly made by the liver, that tells cells to grow and divide. Several growth-hormone peptides work partly by raising it.

Peptides and cancer history: why the IGF-1 question matters

Creator: Halftime Health
Keywords: peptides and cancer risk, IGF-1 and cancer, growth hormone peptides cancer concern

A growth signal that helps tissue repair is the same signal clinicians watch carefully.

TL;DR

Some peptides raise IGF-1, a hormone that tells cells to grow and divide.
Higher IGF-1 has been linked to cancer risk in large population studies.
A personal or family cancer history is a key reason to screen before starting any growth-related peptide.

What it is

IGF-1 (in plain English: insulin-like growth factor 1, a hormone that signals cells to grow) sits at the center of this question. Your liver makes most of it, partly in response to growth hormone. Several popular peptides, such as sermorelin and CJC-1295, work by nudging your body to release more growth hormone, which then raises IGF-1. The same growth signal that helps muscle and tissue repair also tells cells, broadly, to multiply. That dual nature is why clinicians pay attention to it (NIH/PMC review of IGF-1 biology).

How it works

Think of IGF-1 as a “grow” message broadcast to your cells. Healthy cells use that message to repair and maintain tissue. The worry is that abnormal cells can hear the same message. In simple terms, more growth signal may give any fast-dividing cell more encouragement. This does not mean a peptide creates cancer. It means the body’s growth-signaling dial is being turned up, and clinicians prefer to know who is turning it and by how much.

Who asks about it

People come to this topic when they are considering a growth-hormone peptide and have read a warning about IGF-1. Often they have a personal cancer history, a strong family history, or simply a careful streak. The honest question behind the search is: if this peptide raises a growth signal, am I taking a risk I cannot see? It is a smart question to ask before, not after.

What the research says

Large population studies have linked higher IGF-1 levels to a modestly increased risk of certain cancers, including breast and prostate cancer (PubMed meta-analysis of IGF-1 and cancer risk). The key word is linked, not caused. Association studies show patterns across thousands of people; they cannot predict what happens to one person. There is also no published evidence that prescribed growth-hormone peptides cause cancer in humans. The takeaway is balance: a real signal worth respecting, not proof of harm.

What to know before considering it

This is the section that matters most. Any peptide that affects growth signaling should involve a licensed clinician who reviews your full history first. A personal or family history of cancer, active cancer, or unexplained lumps changes the conversation entirely. Clinicians often check a baseline IGF-1 level and may avoid growth-related peptides in higher-risk people. Peptide access always requires a clinician. This topic is one of the clearest reasons why.

The Halftime POV

The second half of life is when this question gets real, because both interest in peptides and cancer risk rise with age. We think the responsible move is to treat IGF-1 as useful information, not a scare headline. Know your number, share your history, and let a clinician weigh the trade-offs with you. Proactive medicine means asking the uncomfortable question early.

Related reading:

FAQ

Q: Do peptides cause cancer? A: No peptide has been shown to cause cancer in people. The narrower concern is that some growth-hormone peptides raise IGF-1, a growth signal linked to cancer risk in population studies. That is why screening matters.

Q: What is IGF-1? A: IGF-1 is insulin-like growth factor 1, a hormone made mostly by the liver that tells cells to grow and divide. Several growth-hormone peptides raise it.

Q: Should I avoid peptides if I have had cancer? A: Not automatically, but a personal or family cancer history is exactly what a clinician needs to know before considering any growth-related peptide.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.